The two-year extension of the contract for the production of injectable specialties and for the terminal packaging of oral specialties for the Italian market has been signed between Pierrel – sector provider for research, development and contract production of medicines – and the pharmaceutical multinational Astrazeneca. Total value of the contract valid until December 2009 – is approximately 3 million euros. The agreement also envisages the possibility of implementing pharmaceutical development activities and support for the updating of product dossiers in the future, with the possibility of extending it to products for other EU markets or other Astrazeneca subsidiaries. Il Sole 24 Ore Sanita' of 19/02/2008 N. 7 19-25 FEBRUARY 2008 p. 25
